More than 25 million Americans filled a GLP-1 receptor agonist prescription in 2025, making semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) two of the most prescribed medications in the country. These drugs profoundly alter glucose metabolism—and a continuous glucose monitor provides the most detailed view of exactly how. CGM data reveals changes that a quarterly A1C test misses: when the drug starts working, how it reshapes the post-meal glucose curve, and whether the dose is optimized.
How GLP-1 Medications Change Glucose Patterns
GLP-1 receptor agonists work through 4 primary mechanisms, all of which are visible on CGM data:
**1. Enhanced insulin secretion.** GLP-1 drugs stimulate the pancreas to release more insulin in response to rising blood sugar—but only when glucose is elevated. This glucose-dependent mechanism means the drug amplifies the natural insulin response after meals without causing low blood sugar during fasting. On a CGM graph, this appears as lower post-meal peaks: a meal that previously spiked to 185 mg/dL might peak at 135 mg/dL after 4-6 weeks of semaglutide.
**2. Suppressed glucagon secretion.** Glucagon is the hormone that signals the liver to release stored glucose. GLP-1 drugs reduce glucagon levels, resulting in lower fasting glucose. CGM users typically observe fasting glucose dropping from 110-130 mg/dL to 85-100 mg/dL over the first 8-12 weeks of treatment.
**3. Delayed gastric emptying.** Semaglutide and tirzepatide slow the rate at which food leaves the stomach, spreading carbohydrate absorption over a longer period. On a CGM, this transforms the glucose curve from a sharp spike to a gentler, broader hill. Post-meal glucose rises more slowly, peaks lower, and returns to baseline faster.
**4. Reduced appetite (central nervous system effect).** While not directly visible on glucose data, reduced caloric intake leads to lower overall glucose exposure. Many CGM users on GLP-1 medications notice that their daily glucose trace flattens significantly simply because they are eating less.
Week-by-Week CGM Changes on Semaglutide
Based on published clinical data and real-world CGM studies, here is the typical glucose evolution during semaglutide dose titration:
**Weeks 1-4 (0.25 mg/week):** Fasting glucose drops by 5-10 mg/dL. Post-meal spikes decrease by 10-20 mg/dL. Time in Range (70-180 mg/dL) improves by 5-8 percentage points. Many users report that the glucose curve visibly "calms down" within the first 2 weeks.
**Weeks 5-8 (0.5 mg/week):** Fasting glucose drops another 5-15 mg/dL. Post-meal peaks rarely exceed 160 mg/dL for typical meals. The overnight glucose trace flattens to a near-horizontal line between 80-95 mg/dL in many patients.
**Weeks 9-16 (1.0 mg/week):** Average glucose approaches near-normal levels. In the SUSTAIN clinical trials, patients on semaglutide 1.0 mg achieved a mean A1C of 6.4 percent (down from 8.1 percent at baseline), corresponding to an average glucose of approximately 137 mg/dL. Time in Range (70-180 mg/dL) exceeded 85 percent for the majority of participants.
**Weeks 17+ (1.0-2.0 mg/week, maintenance):** Glucose patterns stabilize. CGM data at this stage often shows the "non-diabetic pattern"—fasting glucose 80-95 mg/dL, post-meal peaks below 140 mg/dL, Time in Range above 90 percent—in patients whose baseline A1C was 7-9 percent.
Tirzepatide: The Dual-Agonist Difference
Tirzepatide (Mounjaro) acts on both GLP-1 and GIP receptors, producing even larger glucose reductions in clinical trials. The SURPASS-3 trial comparing tirzepatide to insulin degludec showed that tirzepatide 15 mg reduced A1C by 2.37 percentage points—the largest A1C reduction ever recorded in a head-to-head diabetes trial.
On CGM data, tirzepatide users often see virtually flat glucose traces by week 12 of treatment. A 2024 real-world CGM study published in Diabetes Technology & Therapeutics found that patients on tirzepatide 10-15 mg achieved a mean Time in Range (70-180 mg/dL) of 94 percent, compared to 87 percent for patients on semaglutide 1.0 mg.
Why CGM Matters During GLP-1 Treatment
A quarterly A1C test captures the average but misses the detail. CGM data provides 3 advantages during GLP-1 therapy:
**Dose optimization.** If post-meal spikes are still exceeding 180 mg/dL at the current dose, CGM data provides objective evidence for dose escalation. If fasting glucose is consistently below 80 mg/dL, it may signal that the dose is more aggressive than needed—a finding an A1C test would not reveal.
**Hypoglycemia detection.** When GLP-1 medications are combined with insulin or sulfonylureas, the risk of hypoglycemia increases. A CGM with low-glucose alerts (available on Dexcom G7, FreeStyle Libre 3, and Medtronic Guardian 4) provides a safety net that fingerstick testing cannot match.
**Behavioral reinforcement.** Seeing the CGM graph flatten week after week reinforces medication adherence. Patients who can visualize their improvement are more likely to continue treatment—a critical factor given that 30-40 percent of GLP-1 patients discontinue within the first year, often due to side effects they might tolerate if they could see the metabolic benefits in real time.
CGM for Non-Diabetic GLP-1 Users
Millions of people now take semaglutide (as Wegovy) or tirzepatide (as Zepbound) for weight loss without a diabetes diagnosis. For these users, an OTC CGM like Dexcom Stelo or Abbott Lingo can provide valuable data. Research from the STEP clinical trials showed that even non-diabetic participants on semaglutide experienced measurable improvements in glucose variability—average glucose dropped from 99 mg/dL to 91 mg/dL, and post-meal peaks decreased by 15-20 mg/dL.
For anyone on a GLP-1 medication, a continuous glucose monitor transforms treatment from a blind trust in weekly injections into a data-driven process with visible, daily confirmation that the drug is working.